MAM
RNAC icon

Meeder Asset Management’s Cartesian Therapeutics RNAC Stock Holding History

Meeder Asset Management’s Portfolio RNAC Stock Details RNAC Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2018
Q4 		– Sell
-3
Closed -$1K – 1783
2018
Q3 		$1K Buy
+3
New +$1.21K ﹤0.01% 1487
2017
Q2 		– Sell
-1
Closed – – 1831
2017
Q1 		$0 Buy
+1
New +$421 ﹤0.01% 1719

Other funds holding RNAC

PVMCV
Polaris Venture Management Co V Boston, Massachusetts $14.1M AUM 121.41% 1-Year Est. Return
O
OrbiMed New York $5.05B AUM 125.28% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
JP Morgan Chase
JP Morgan Chase New York $1.56T AUM 27.86% 1-Year Est. Return
KCM
Kennedy Capital Management St Louis, Missouri $4.72B AUM 36.69% 1-Year Est. Return
AG
Artal Group Luxembourg $1.01B AUM 29.84% 1-Year Est. Return
VC
Vivo Capital Palo Alto, California $1.2B AUM 911.44% 1-Year Est. Return
Man Group
Man Group London, United Kingdom $55.1B AUM 24.23% 1-Year Est. Return
SRF
Silver Rock Financial Los Angeles, California $49.7M AUM 17.42% 1-Year Est. Return
Fidelity Investments
Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return

Meeder Asset Management's RNAC Position: Q4 2018 in Review

Meeder Asset Management sold out of Cartesian Therapeutics (RNAC) in Q4 2018, closing a stake of 3 shares — an estimated $1K sold.

Meeder Asset Management first reported a position in RNAC in Q1 2017 and held it in 2 quarters. The position peaked at $1K in Q3 2018. 54 funds tracked by Wall St. Rank hold RNAC as of Q4 2018.

  • Meeder Asset Management reported no remaining Cartesian Therapeutics position as of Q4 2018 after selling out during the quarter.
  • Meeder Asset Management sold 3 Cartesian Therapeutics shares in Q4 2018, an estimated $1K.
  • Meeder Asset Management first reported a position in Cartesian Therapeutics in Q1 2017 and held it in 2 quarters.
  • Meeder Asset Management's Cartesian Therapeutics position peaked at $1K in Q3 2018.
  • 54 funds tracked by Wall St. Rank held Cartesian Therapeutics as of Q4 2018.

Based on Meeder Asset Management's 13F filing for Q4 2018, filed 17 Jan 2019.